Announcements Trials

Browse Landscape

Phase

Phase 1 10 Phase 1/2 2 Phase 3 1 Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 19 Carcinoma 4 NSCLC 3 Lung Neoplasms 3 Neoplasm Metastasis 2 Stage IB-IIIA Non-small Cell Lung Carcinoma 1 Non-small Cell Carcinoma 1 Neoplasms 1 Neoplasm, Residual 1 NSCLC Patients With Brain Metastasis 1 Locally Advanced or Metastatic Non-squamous NSCLC 1 Locally Advanced or Metastatic EGFR T790M+ NSCLC 1 Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer 1 Bronchial Neoplasms 1 Brain Neoplasms 1 Anticancer Treatment 1

Interventions

Paclitaxel 20 Gemcitabine 16 Dexamethasone 16 Bevacizumab 16 Docetaxel 15 Oxaliplatin 14 Cyclophosphamide 13 Carboplatin 12 Capecitabine 12 Sorafenib 11 Fluorouracil 11 Leucovorin 10 Cisplatin 10 pembrolizumab 9 Pemetrexed 9 Epoetin Alfa 9 venetoclax 8 Prednisone 8 Fentanyl 8 Drug Therapy 8 Doxorubicin 8 atezolizumab 7 Rivaroxaban 7 Rituximab 7 Darbepoetin alfa 7 Anastrozole 7 Panitumumab 6 Ondansetron 6 Morphine 6 Irinotecan 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Neoplasms × osimertinib × Clear all

NCT05629234 2026-04-06

ROSY-T

AstraZeneca

Phase 3 Active not recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡